<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594434</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01914-35</org_study_id>
    <nct_id>NCT04594434</nct_id>
  </id_info>
  <brief_title>Eye Movement Desensitization and Reprocessing (EMDR) in Complex Psychotrauma</brief_title>
  <official_title>Efficiency of the Use of Benevolent Memories in the EMDR Protocol in Complex Psychotrauma (Benevolence Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study wants to demonstrate the effectiveness of combining a positive memory with&#xD;
      &quot;recommended&quot; therapy based on EMDR in reducing the disturbance that patients with complex&#xD;
      psychotrauma may experience. The positive memory will be called &quot;benevolent memory&quot; (SB) or&#xD;
      &quot;less worse memory&quot; (SMP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional study, prospective, exploratory, comparative, randomized,&#xD;
      controlled versus reference treatment protocol, open.&#xD;
&#xD;
      Patients will be seen 16 times for the purposes of the study. They will be hospitalized&#xD;
      during therapy. Discharge from hospitalization occurs during follow-up depending on the&#xD;
      patient's condition.&#xD;
&#xD;
      They will be evaluated over a period of 4 to 6 weeks between the start (Day 0 = Week 1) and&#xD;
      the end of treatment (visit week 12). These visits will coincide with treatment sessions with&#xD;
      the EMDR ± SB / SMP protocol, as part of the support of their complex psychotrauma. At the&#xD;
      end of treatment, the patient will be evaluated during follow-up visits at Month 1, Month 3&#xD;
      and Month 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the combination of SB and / or PMS with EMDR technique on reducing the disturbance experienced by patients with complex psychotrauma.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with a 50% reduction in the SUD score(44/5000 measured by the SUD scale ranging from 0 to 10) at the end of the 3rd &quot;active&quot; EMDR session compared to the pre-treatment score of the 1st &quot;active&quot; session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disturbance felt</measure>
    <time_frame>6 months</time_frame>
    <description>The % of patients responding to therapy (with SUD scores = 0 and VOC = 7) at M1, M3 and M6 will be compared between the 2 groups by a Cochran-Mantel-Haenszel test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of dissociation</measure>
    <time_frame>6 months</time_frame>
    <description>The change in the level of dissociation by the DES II scale (score from 0 to 100) after therapy will be compared between the 2 groups by an analysis of covariance with adjustment for the score at inclusion;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Complex Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>protocol EMDR + SB / SMP protocol (adjusted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Association of a positive memory with the &quot;recommended&quot; therapy based on EMDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>protocol EMDR (standard).</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;recommended&quot; therapy based on EMDR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Scale SUD</intervention_name>
    <description>Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions</description>
    <arm_group_label>protocol EMDR (standard).</arm_group_label>
    <arm_group_label>protocol EMDR + SB / SMP protocol (adjusted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VOC scale</intervention_name>
    <description>The VOC (Validity Of Cognition) scale is a scale of value given to cognition.</description>
    <arm_group_label>protocol EMDR (standard).</arm_group_label>
    <arm_group_label>protocol EMDR + SB / SMP protocol (adjusted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DES II scale</intervention_name>
    <description>The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.</description>
    <arm_group_label>protocol EMDR (standard).</arm_group_label>
    <arm_group_label>protocol EMDR + SB / SMP protocol (adjusted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient suffering from a combination of a period of complex trauma and a disturbance&#xD;
             triggered by situations in adulthood;&#xD;
&#xD;
          -  Having signed an informed consent form to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Protected patient (under legal protection, or deprived of liberty by judicial or&#xD;
             administrative decision);&#xD;
&#xD;
          -  Patient seeking legal benefit from participating in the study;&#xD;
&#xD;
          -  Patient previously treated with EMDR;&#xD;
&#xD;
          -  Patient unable to understand the information related to the study (linguistic,&#xD;
             psychological, cognitive reason, etc.);&#xD;
&#xD;
          -  Untreated epileptic patient;&#xD;
&#xD;
          -  Patient with severe oculomotor disorders;&#xD;
&#xD;
          -  Patient in hypomanic phase;&#xD;
&#xD;
          -  Patient treated with high dose corticosteroids;&#xD;
&#xD;
          -  Patient with alcohol and / or drug misuse in the 7 days preceding inclusion;&#xD;
&#xD;
          -  Pregnant or likely to be (of childbearing age, without effective contraception) or&#xD;
             breastfeeding;&#xD;
&#xD;
          -  Patient participating in another clinical trial, or in a period of exclusion from&#xD;
             another clinical trial;&#xD;
&#xD;
          -  Patient not beneficiary of a social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Didier DONNEAU, MD</last_name>
    <phone>01 30 46 68 04</phone>
    <email>drdonneau@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique d'Yveline</name>
      <address>
        <city>Vieille-eglise-en Yvelines</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DONNEAU, MD</last_name>
      <phone>01 30 46 68 04</phone>
      <email>drdonneau@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

